ATP結(jié)合盒轉(zhuǎn)運(yùn)體（ABC轉(zhuǎn)運(yùn)體）介導(dǎo)的多藥耐藥（MDR）是肝癌化療失敗的主要原因，研究確定天然的及獲得性MDR的產(chǎn)生機(jī)制，有利于提出更有效的治療措施。針對(duì)ATP結(jié)合盒轉(zhuǎn)運(yùn)體的腫瘤MDR逆轉(zhuǎn)策略，對(duì)于肝癌化療效果的提高具有重要意義。此外，ATP結(jié)合盒轉(zhuǎn)運(yùn)體可能參與了腫瘤生物學(xué)的一些重要過(guò)程，發(fā)揮藥物外排泵以外的作用，為腫瘤的治療提供了新的研究方向。

The failure of chemotherapy in liver cancer treatment often occurs as a result of multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters and the development of more effective therapies depends on identifying the mechanisms of intrinsic or acquired MDR. Strategies focused on ABC transporters to overcome MDR have a lot of benefits on the chemotherapy of liver cancer. Furthermore, considerable evidence suggests that the ABC transporters play a fundamental role in tumor biology beyond the efflux of cytotoxic drugs, which indicates a new way of study on cancer therapy.

國(guó)家自然科學(xué)基金項(xiàng)目（81072694, 30873118）